Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Procyon's average Accounts Receivable for the
three
months ended in Jun. 2024 was $0.50 Mil. Procyon's Revenue for the
three
months ended in Jun. 2024 was $1.41 Mil.
Hence, Procyon's Days Sales Outstanding for the
three
months ended in Jun. 2024 was 32.13.
The historical rank and industry rank for Procyon's Days Sales Outstanding or its related term are showing as below:
PCYN's Days Sales Outstanding is not ranked *
in the Drug Manufacturers industry.
Industry Median: 72.18 * Ranked among companies with meaningful Days Sales Outstanding only.
Procyon's Days Sales Outstanding
declined
from Jun. 2023 (38.22) to Jun. 2024 (32.13).
Procyon (OTCPK:PCYN) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Procyon Days Sales Outstanding Related Terms
Procyon Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Procyon's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PCYN vs KAYS, YCBD, CBDY: Days Sales Outstanding Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Procyon's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Procyon Days Sales Outstanding vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Procyon's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Procyon's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Procyon (PCYN) has a Days Sales Outstanding of 32.13 as of Jun. 2024. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Procyon and its competitors.
Is Procyon's Days Sales Outstanding too high?
Procyon's current Days Sales Outstanding is 32.13. The Drug Manufacturers industry median Days Sales Outstanding is 72.18. Procyon's value of 32.13 is 55.5% below this industry median. Overall, Procyon has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Procyon's Days Sales Outstanding compare to KAYS and YCBD?
Procyon's Days Sales Outstanding of 32.13 can be compared against companies in the Drug Manufacturers industry. The industry median Days Sales Outstanding is 72.18. Procyon's value of 32.13 is 55.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Drug Manufacturers company?
The median Days Sales Outstanding among Drug Manufacturers companies is 72.18, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Procyon's current Days Sales Outstanding of 32.13 is 55.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Procyon and its competitors. For the Drug Manufacturers industry, the median Days Sales Outstanding is 72.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Procyon's current Days Sales Outstanding is 32.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Procyon stock overvalued right now?
Procyon (PCYN) has a current Days Sales Outstanding of 32.13. The current Days Sales Outstanding is 32.13 and 55.5% below the Drug Manufacturers industry median of 72.18. Procyon's overall GF Score™ is 48/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Procyon (PCYN), the current Days Sales Outstanding is 32.13 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Procyon Corp is a United-based company, through its subsidiary, it is engaged in developing and marketing proprietary medical products used to treat pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems. Its wound care products are sold through distributors to institutional customers such as hospitals, wound care clinics, skilled nursing facilities, home health agencies, and physicians and other healthcare practitioners. The firm's product lines are AMERX, AMERIGEL, and HELIX3 Bioactive Collagen. The skin and wound care products are marketed under the trademark AMERIGEL which contains the proprietary ingredient OAKIN which promotes wound healing and healthy skin. The corporation markets its products in the United States.
48GF Score
Get the complete analysis for PCYN
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCYN has been successfully added to your 
